ArticleClinical rheumatology2026
Pharmacodynamic evaluation and mechanism study of cord blood nucleated cell extract in the treatment of rheumatoid arthritis.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the effectiveness of cord blood nucleated cell extract (CBNCE) in rheumatoid arthritis (RA) and explore the mechanism preliminarily.
methodsCBNCE injection was prepared by adding HClO
resultsThe average inhibitory rate of CBNCE on lymphocyte proliferation was 83.51%. Compared with the model group, rats in the CBNCE group showed a decrease of inflammatory cell infiltration in ankle tissue. The left hindfoot volume (days 5, 9, 10, and 12-21), Th17 percentage and Th17/Treg ratio in peripheral blood, and the levels of IL-1, IL-6, IL-8, and IL-17 in ankle effusion, as well as the MMP-3 protein expression in synovial tissue were significantly decreased (P < 0.05). There were significant (P < 0.05) increases in the fluorescence intensity of Aggrecan and Collagen type I, as well as in the amounts of IL-4 and IL-10.
conclusionCBNCE modulates the Th17/Treg balance by decreasing the Th17 cells, suppressing the secretion of IL-1, IL-6, IL-8, and IL-17, enhancing the secretion of IL-4 and IL-10, and further inhibiting the expression of MMP-3 protein, thereby increasing the level of Aggrecan and Collagen type I. Ultimately, CBNCE alleviates RA. Key Points • Our study was the first to explore the effect and mechanism of cord blood nucleated cell extract in the treatment of rheumatoid arthritis. • This study offers a theoretical foundation and introduces a novel concept for utilizing cord blood in the treatment of rheumatoid arthritis.
Indexed as
Identifiers
41863717What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.